Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England
Journal of Medical Economics - United Kingdom
doi 10.1080/13696998.2018.1461630
Full Text
Open PDFAbstract
Available in full text
Categories
Date
April 16, 2018
Authors
Publisher
Informa UK Limited